These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15550154)

  • 1. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression.
    Ito K; Hara H; Okada T; Shimojima H; Suzuki H
    Clin Exp Dermatol; 2004 Nov; 29(6):679-80. PubMed ID: 15550154
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.
    Romanelli P; Schlam E; Green JB; Trent JT; Ricotti C; Elgart GW; Kirsner RS; Kerdel FA
    G Ital Dermatol Venereol; 2008 Aug; 143(4):229-33. PubMed ID: 18833079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis.
    Chang HY; Cooper ZA; Swetter SM; Marinkovich MP
    Arch Dermatol; 2004 Feb; 140(2):242-4. PubMed ID: 14967808
    [No Abstract]   [Full Text] [Related]  

  • 4. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Yeung CK; Lam LK; Chan HH
    Clin Exp Dermatol; 2005 Sep; 30(5):600-2. PubMed ID: 16045716
    [No Abstract]   [Full Text] [Related]  

  • 5. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition.
    French LE; Tschopp J
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1656-61. PubMed ID: 11103436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidermic necrolysis: advances in pathogenesis].
    Roujeau JC
    Ann Dermatol Venereol; 2000 May; 127(5):546-7. PubMed ID: 10863193
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxic epidermal necrolysis: current evidence, practical management and future directions.
    Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
    Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
    Viard I; Wehrli P; Bullani R; Schneider P; Holler N; Salomon D; Hunziker T; Saurat JH; Tschopp J; French LE
    Science; 1998 Oct; 282(5388):490-3. PubMed ID: 9774279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study.
    Lan CC; Wu CS; Tsai PC; Chen GS
    Acta Derm Venereol; 2006; 86(3):215-8. PubMed ID: 16710577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis.
    Stella M; Clemente A; Bollero D; Risso D; Dalmasso P
    Burns; 2007 Jun; 33(4):452-9. PubMed ID: 17475410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
    Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
    Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulins in the treatment of severe drug eruptions.
    Bachot N; Roujeau JC
    Curr Opin Allergy Clin Immunol; 2003 Aug; 3(4):269-74. PubMed ID: 12865770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis: review of pathogenesis and management.
    Downey A; Jackson C; Harun N; Cooper A
    J Am Acad Dermatol; 2012 Jun; 66(6):995-1003. PubMed ID: 22169256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
    Sidwell RU; Swift S; Yan CL; Porter W; Thompson EM; Clark JA; Bunker CB
    Int J Clin Pract; 2003 Sep; 57(7):643-5. PubMed ID: 14529073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.
    Lissia M; Figus A; Rubino C
    Br J Plast Surg; 2005 Jun; 58(4):504-10. PubMed ID: 15897036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
    Trent J; Halem M; French LE; Kerdel F
    Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of apoptosis stimulus factor and its ligand in the induction of apoptosis in some ultraviolet induced diseases.
    Shaker O; Youssef R
    Dermatol Online J; 2006 Mar; 12(3):4. PubMed ID: 16638418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.